These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35871679)

  • 1. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
    Kuc J; Kettner H; Rosas F; Erritzoe D; Haijen E; Kaelen M; Nutt D; Carhart-Harris RL
    Psychopharmacology (Berl); 2022 May; 239(5):1425-1440. PubMed ID: 34734314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry.
    Milshteyn Y; Bensimon M
    Harm Reduct J; 2023 Dec; 20(1):176. PubMed ID: 38057811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users.
    St Arnaud KO; Sharpe D
    J Psychoactive Drugs; 2023; 55(1):30-39. PubMed ID: 35156542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic pleasures: An affective understanding of the joys of tripping.
    Bøhling F
    Int J Drug Policy; 2017 Nov; 49():133-143. PubMed ID: 28918193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    J Affect Disord; 2023 Apr; 326():105-110. PubMed ID: 36720405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Set and Setting for Psychedelic Harm Reduction.
    Hartogsohn I
    Curr Top Behav Neurosci; 2024 Jul; ():. PubMed ID: 39080241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-Care Practices with Psychedelics - A Qualitative Study of Users' Perspectives.
    Soares CM; Leite Â; Pinto M
    J Psychoactive Drugs; 2023; 55(2):159-169. PubMed ID: 35574941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder.
    Spriggs MJ; Kettner H; Carhart-Harris RL
    Eat Weight Disord; 2021 May; 26(4):1265-1270. PubMed ID: 32895801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing.
    Qiu TT; Minda JP
    J Psychoactive Drugs; 2023; 55(2):123-133. PubMed ID: 35438609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
    Wolff M; Evens R; Mertens LJ; Schmidt C; Beck J; Rutrecht H; Cherniak AD; Gründer G; Jungaberle H
    J Psychopharmacol; 2024 May; 38(5):432-457. PubMed ID: 38742761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada.
    Haeny AM; Lopez JA; Colón Grigas PA; Crouch MC; Davis AK; Williams M
    J Subst Use Addict Treat; 2023 Jun; 149():209035. PubMed ID: 37019336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey.
    Evens R; Reiche S; Marek RM; Moon DU; Groß RE; Romanello A; Jalilzadeh Masah D; Scicchitano Böckheler M; Gutwinski S; Montag C; Mick I; Majić T
    Front Psychiatry; 2021; 12():732028. PubMed ID: 34803757
    [No Abstract]   [Full Text] [Related]  

  • 20. Psychedelic Experiences After Bereavement Improve Symptoms of Grief: The Influence of Emotional Breakthroughs and Challenging Experiences.
    Low F; Earleywine M
    J Psychoactive Drugs; 2024; 56(3):316-323. PubMed ID: 37343940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.